Raymond J.  Land net worth and biography

Raymond Land Biography and Net Worth

Director of Anika Therapeutics
Mr. Land joined the Board of Directors of Anika Therapeutics in January 2006. Previously, Mr. Land served as chairman of the board of directors of BioAmber, Inc., a publicly traded company developing chemicals from renewable feedstocks, and in 2017 also served as the interim Chief Financial Officer of BioAmber, Inc. for approximately three months. From 2008 through 2010, Mr. Land served as the Senior Vice President and Chief Financial Officer of Clarient, Inc., an advanced molecular diagnostics company. From June 2007 to June 2008, he was the Senior Vice President and Chief Financial Officer of Safeguard Scientifics, Inc., a venture capital firm. Prior to Safeguard Scientifics, Inc., Mr. Land held executive management and Chief Financial Officer positions at Medcenter Solutions, Inc., a pharmaceutical marketing company where he was also a board member, and Orchid Cellmark, a provider of DNAtesting services. Mr. Land previously served as Senior Vice President and Chief Financial Officer for Genencor International, Inc., a biotechnology company focusing on bioproducts and healthcare, from 1997 until its acquisition in April 2005. From 1991 to 1996, he served as Senior Vice President and Chief Financial Officer for West Pharmaceutical Services, Inc. Previously, Mr. Land was with Campbell Soup Company, Inc. where for nine years he held increasingly senior financial positions and also served as General Manager of a frozen food division. Prior to joining Campbell Soup, he was with Coopers and Lybrand for nine years. Mr. Land is a retired Certified Public Accountant and has a B.S. degree in accounting and finance from Temple University. Mr. Land's qualifications for membership on the Board include his extensive prior experience as chief financial officer at multiple companies, including several in the life science industry. He serves as the Chair and designated financial expert on the Audit Committee and as a member of the Governance and Nominating Committee.

What is Raymond J. Land's net worth?

The estimated net worth of Raymond J. Land is at least $202,006.20 as of May 12th, 2021. Mr. Land owns 7,953 shares of Anika Therapeutics stock worth more than $202,006 as of March 28th. This net worth approximation does not reflect any other investments that Mr. Land may own. Learn More about Raymond J. Land's net worth.

How do I contact Raymond J. Land?

The corporate mailing address for Mr. Land and other Anika Therapeutics executives is 32 WIGGINS AVENUE, BEDFORD MA, 01730. Anika Therapeutics can also be reached via phone at (781) 457-9000 and via email at [email protected]. Learn More on Raymond J. Land's contact information.

Has Raymond J. Land been buying or selling shares of Anika Therapeutics?

Raymond J. Land has not been actively trading shares of Anika Therapeutics over the course of the past ninety days. Most recently, Raymond J. Land sold 2,000 shares of the business's stock in a transaction on Wednesday, May 12th. The shares were sold at an average price of $42.60, for a transaction totalling $85,200.00. Following the completion of the sale, the director now directly owns 7,953 shares of the company's stock, valued at $338,797.80. Learn More on Raymond J. Land's trading history.

Who are Anika Therapeutics' active insiders?

Anika Therapeutics' insider roster includes John Hennemann, III (Director), Raymond Land (Director), and Michael Levitz (CFO). Learn More on Anika Therapeutics' active insiders.

Raymond J. Land Insider Trading History at Anika Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/12/2021Sell2,000$42.60$85,200.007,953View SEC Filing Icon  
2/26/2020Sell2,700$42.68$115,236.0016,099View SEC Filing Icon  
7/29/2019Sell3,000$55.44$166,320.0011,992View SEC Filing Icon  
2/26/2019Sell4,000$33.06$132,240.0018,992View SEC Filing Icon  
2/25/2016Sell2,695$43.62$117,555.9014,165View SEC Filing Icon  
2/27/2015Sell4,621$39.49$182,483.29View SEC Filing Icon  
See Full Table

Raymond J. Land Buying and Selling Activity at Anika Therapeutics

This chart shows Raymond J Land's buying and selling at Anika Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Anika Therapeutics Company Overview

Anika Therapeutics logo
Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and bone preserving joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief; and Hyvisc, a molecular weight injectable HA veterinary product. The company's joint preservation and restoration product family comprises 150 bone preserving joint technology products, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and orthopedic regenerative solutions, including Hyalofast and Tactoset. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including adhesion barrier, advanced wound care, ear, nose, and throat products, as well as ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.
Read More

Today's Range

Now: $25.40
Low: $25.24
High: $25.62

50 Day Range

MA: $24.61
Low: $22.24
High: $26.42

2 Week Range

Now: $25.40
Low: $16.54
High: $29.25

Volume

83,692 shs

Average Volume

85,880 shs

Market Capitalization

$377.19 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.75